ArticleJournal of cellular and molecular medicine2026
High ALG1 Expression Is Correlated With Poor Prognosis and the Immune Microenvironment in Glioma.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glioma is the most prevalent primary tumour in the central nervous system. This study investigates ALG1 expression in glioma and its clinical significance. Using the TCGA and CGGA databases, a bioinformatics analysis examines ALG1 expression, its prognostic value, and its link to the immune microenvironment. Clinical samples are analysed using RT-qPCR, Western blotting, and immunohistochemistry/fluorescence for expression validation. Single-cell RNA sequencing (scRNA-seq) assesses ALG1's role in cell state transitions. In vitro, wound healing assays are performed after ALG1 knockdown with siRNA, and in vivo analysis uses an in situ mouse model. The pan-cancer analysis revealed that ALG1 is significantly overexpressed in varioustumours, including glioblastoma (GBM), and is linked to poor patient outcomes. A prognostic nomogram based on ALG1 levels accurately predicted 1-, 3-, and 5-year survival rates for glioma patients. In clinical samples, ALG1 was highly expressed at both mRNA and protein levels, correlating with tumour grade. Single-cell analysis showed increasing ALG1 expression from non-tumorigenic to malignant states, especially in malignant cells. ALG1 overexpression altered tumour microenvironmentsignalling, changing IL10 and CYPA pathways associated with immune suppression. Knocking down ALG1 significantly reduced glioma cell migration and downregulated EMT-related proteins like N-cadherin, β-catenin, and Vimentin. This study highlights ALG1 as a key prognostic biomarker and therapeutic target for glioma, promoting malignancy through increased cell migration, EMT modulation, and an altered immunosuppressive microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.